rat cd86 ig Search Results


96
Proteintech mouse anti cd68
Mouse Anti Cd68, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/ppr0443654-88-72-82?v=Proteintech
Average 96 stars, based on 1 article reviews
mouse anti cd68 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

93
ATCC anti b7 2
Anti B7 2, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pm11509599-71-5-21?v=ATCC
Average 93 stars, based on 1 article reviews
anti b7 2 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

96
Proteintech rabbit polyclonal anti cd 86
Rabbit Polyclonal Anti Cd 86, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pmc09719652-113-64-70?v=Proteintech
Average 96 stars, based on 1 article reviews
rabbit polyclonal anti cd 86 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Proteintech anti cd86
Anti Cd86, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pmc12977715-54-7-12?v=Proteintech
Average 96 stars, based on 1 article reviews
anti cd86 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

90
Becton Dickinson fluorescence-conjugated anti-i-ab
Fluorescence Conjugated Anti I Ab, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pm21360699-169-7-17?v=Becton+Dickinson
Average 90 stars, based on 1 article reviews
fluorescence-conjugated anti-i-ab - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

99
NSJ Bioreagents il-4 antibody
Il 4 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/custom%40v8351%4010725710?v=NSJ+Bioreagents
Average 99 stars, based on 1 article reviews
il-4 antibody - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

93
Proteintech pe cd86
a The percentages of DC maturation in tumors following different treatments (gated on CD11c + DC cells). b The percentages of tumoral CD4 + and CD8 + T cells following various treatments (gated on CD3 + T cells). The cytokines secretion of TNF-α ( c ) IFN-γ ( d ) and IL-1β ( e ) in serum following various treatments. The percentages ( f ) and statistical analysis ( g ) of M1 and M2 TAMs after different treatments (gated on F4/80 macrophages). h Immunofluorescent staining <t>(M1-CD86)</t> of tumor sections after different treatment. i The cytokine secretion of IL-6 and IL-10 in serum following different treatments. The gating strategy is presented in Fig. . For all figures here, data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of the Control group. P values were presented in absolute value in the figures.
Pe Cd86, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pmc11873056-329-19-20?v=Proteintech
Average 93 stars, based on 1 article reviews
pe cd86 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

96
Proteintech arg 1
a The percentages of DC maturation in tumors following different treatments (gated on CD11c + DC cells). b The percentages of tumoral CD4 + and CD8 + T cells following various treatments (gated on CD3 + T cells). The cytokines secretion of TNF-α ( c ) IFN-γ ( d ) and IL-1β ( e ) in serum following various treatments. The percentages ( f ) and statistical analysis ( g ) of M1 and M2 TAMs after different treatments (gated on F4/80 macrophages). h Immunofluorescent staining <t>(M1-CD86)</t> of tumor sections after different treatment. i The cytokine secretion of IL-6 and IL-10 in serum following different treatments. The gating strategy is presented in Fig. . For all figures here, data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of the Control group. P values were presented in absolute value in the figures.
Arg 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pmc12181029-123-17-19?v=Proteintech
Average 96 stars, based on 1 article reviews
arg 1 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Proteintech il 10
a The percentages of DC maturation in tumors following different treatments (gated on CD11c + DC cells). b The percentages of tumoral CD4 + and CD8 + T cells following various treatments (gated on CD3 + T cells). The cytokines secretion of TNF-α ( c ) IFN-γ ( d ) and IL-1β ( e ) in serum following various treatments. The percentages ( f ) and statistical analysis ( g ) of M1 and M2 TAMs after different treatments (gated on F4/80 macrophages). h Immunofluorescent staining <t>(M1-CD86)</t> of tumor sections after different treatment. i The cytokine secretion of IL-6 and IL-10 in serum following different treatments. The gating strategy is presented in Fig. . For all figures here, data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of the Control group. P values were presented in absolute value in the figures.
Il 10, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pm41271555-466-18-19?v=Proteintech
Average 96 stars, based on 1 article reviews
il 10 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

99
Biotium cd3e, mouse(145-2c11)
a The percentages of DC maturation in tumors following different treatments (gated on CD11c + DC cells). b The percentages of tumoral CD4 + and CD8 + T cells following various treatments (gated on CD3 + T cells). The cytokines secretion of TNF-α ( c ) IFN-γ ( d ) and IL-1β ( e ) in serum following various treatments. The percentages ( f ) and statistical analysis ( g ) of M1 and M2 TAMs after different treatments (gated on F4/80 macrophages). h Immunofluorescent staining <t>(M1-CD86)</t> of tumor sections after different treatment. i The cytokine secretion of IL-6 and IL-10 in serum following different treatments. The gating strategy is presented in Fig. . For all figures here, data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of the Control group. P values were presented in absolute value in the figures.
Cd3e, Mouse(145 2c11), supplied by Biotium, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/custom%40bnc042013-100%4019933856?v=Biotium
Average 99 stars, based on 1 article reviews
cd3e, mouse(145-2c11) - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

90
Federation of European Neuroscience Societies ctla4-ig
a The percentages of DC maturation in tumors following different treatments (gated on CD11c + DC cells). b The percentages of tumoral CD4 + and CD8 + T cells following various treatments (gated on CD3 + T cells). The cytokines secretion of TNF-α ( c ) IFN-γ ( d ) and IL-1β ( e ) in serum following various treatments. The percentages ( f ) and statistical analysis ( g ) of M1 and M2 TAMs after different treatments (gated on F4/80 macrophages). h Immunofluorescent staining <t>(M1-CD86)</t> of tumor sections after different treatment. i The cytokine secretion of IL-6 and IL-10 in serum following different treatments. The gating strategy is presented in Fig. . For all figures here, data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of the Control group. P values were presented in absolute value in the figures.
Ctla4 Ig, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/10__1111_slash_j__1574___695x__2011__00816__x-144-58-28?v=Federation+of+European+Neuroscience+Societies
Average 90 stars, based on 1 article reviews
ctla4-ig - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

96
Proteintech foxo3a
Targeting miR-1293 may boost T cell-mediated anti-tumor immunity and prolonged prognosis in PDAC. (A) Representative microscopic picture for cocultured PDOs and CAFs (Bright field). (B-C) Transfection of CAFs with miR-1293 mimic and inhibitor affects PD-1 expression in co-cultured T cells (mean ± SD). (D) Inhibiting miR-1293 in CAFs enhances apoptosis in co-cultured PDOs under T cell assault. (E) T cells co-cultured with CAFs of varying transfections exhibit distinct cytotoxicity (mean ± SD). (F) miR-1293 expression in PDAC cells modestly influences cell proliferation (mean ± SD). (G) KEGG analysis unveiled dysregulation of genes associated with glycolysis/gluconeogenesis in correlation with miR-1293 levels. (H) In PDACs exhibiting high miR-1293 levels, four glycolytic genes exhibited upregulation. (I) Heatmap showed the differences of metabolites abundance between two groups with indicated treatment. (J-K) Integrated analysis identified <t>FOXO3</t> as a potentially downregulated TF with a potential interaction with miR-1293 in PDACs. (L-M) The results of a luciferase reporter assay provided supporting evidence for the binding of miR-1293 to FOXO3 mRNA (mean ± SD). (N) Western blot analysis demonstrated that miR-1293 reduces the expression of FOXO3.
Foxo3a, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+cd86+ig/pmc11059144-165-12-13?v=Proteintech
Average 96 stars, based on 1 article reviews
foxo3a - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

Image Search Results


a The percentages of DC maturation in tumors following different treatments (gated on CD11c + DC cells). b The percentages of tumoral CD4 + and CD8 + T cells following various treatments (gated on CD3 + T cells). The cytokines secretion of TNF-α ( c ) IFN-γ ( d ) and IL-1β ( e ) in serum following various treatments. The percentages ( f ) and statistical analysis ( g ) of M1 and M2 TAMs after different treatments (gated on F4/80 macrophages). h Immunofluorescent staining (M1-CD86) of tumor sections after different treatment. i The cytokine secretion of IL-6 and IL-10 in serum following different treatments. The gating strategy is presented in Fig. . For all figures here, data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of the Control group. P values were presented in absolute value in the figures.

Journal: Nature Communications

Article Title: In situ valence-transited arsenic nanosheets for multi-modal therapy of colorectal cancer

doi: 10.1038/s41467-025-57376-7

Figure Lengend Snippet: a The percentages of DC maturation in tumors following different treatments (gated on CD11c + DC cells). b The percentages of tumoral CD4 + and CD8 + T cells following various treatments (gated on CD3 + T cells). The cytokines secretion of TNF-α ( c ) IFN-γ ( d ) and IL-1β ( e ) in serum following various treatments. The percentages ( f ) and statistical analysis ( g ) of M1 and M2 TAMs after different treatments (gated on F4/80 macrophages). h Immunofluorescent staining (M1-CD86) of tumor sections after different treatment. i The cytokine secretion of IL-6 and IL-10 in serum following different treatments. The gating strategy is presented in Fig. . For all figures here, data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of the Control group. P values were presented in absolute value in the figures.

Article Snippet: The tumors were stained with primary antibodies against the following proteins: CBS (Proteintech, Cat 67861-1-Ig), P53 (Proteintech, Cat 60283-2-lg), PE-CD86 (Proteintech, Cat PE-65068), PE-CD8 (Proteintech, Cat PE-65069), Dylight 594-Goat Anti Mouse IgG (Immunoway, RS23410).

Techniques: Staining, Comparison, Control

Targeting miR-1293 may boost T cell-mediated anti-tumor immunity and prolonged prognosis in PDAC. (A) Representative microscopic picture for cocultured PDOs and CAFs (Bright field). (B-C) Transfection of CAFs with miR-1293 mimic and inhibitor affects PD-1 expression in co-cultured T cells (mean ± SD). (D) Inhibiting miR-1293 in CAFs enhances apoptosis in co-cultured PDOs under T cell assault. (E) T cells co-cultured with CAFs of varying transfections exhibit distinct cytotoxicity (mean ± SD). (F) miR-1293 expression in PDAC cells modestly influences cell proliferation (mean ± SD). (G) KEGG analysis unveiled dysregulation of genes associated with glycolysis/gluconeogenesis in correlation with miR-1293 levels. (H) In PDACs exhibiting high miR-1293 levels, four glycolytic genes exhibited upregulation. (I) Heatmap showed the differences of metabolites abundance between two groups with indicated treatment. (J-K) Integrated analysis identified FOXO3 as a potentially downregulated TF with a potential interaction with miR-1293 in PDACs. (L-M) The results of a luciferase reporter assay provided supporting evidence for the binding of miR-1293 to FOXO3 mRNA (mean ± SD). (N) Western blot analysis demonstrated that miR-1293 reduces the expression of FOXO3.

Journal: Computational and Structural Biotechnology Journal

Article Title: Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma

doi: 10.1016/j.csbj.2024.04.021

Figure Lengend Snippet: Targeting miR-1293 may boost T cell-mediated anti-tumor immunity and prolonged prognosis in PDAC. (A) Representative microscopic picture for cocultured PDOs and CAFs (Bright field). (B-C) Transfection of CAFs with miR-1293 mimic and inhibitor affects PD-1 expression in co-cultured T cells (mean ± SD). (D) Inhibiting miR-1293 in CAFs enhances apoptosis in co-cultured PDOs under T cell assault. (E) T cells co-cultured with CAFs of varying transfections exhibit distinct cytotoxicity (mean ± SD). (F) miR-1293 expression in PDAC cells modestly influences cell proliferation (mean ± SD). (G) KEGG analysis unveiled dysregulation of genes associated with glycolysis/gluconeogenesis in correlation with miR-1293 levels. (H) In PDACs exhibiting high miR-1293 levels, four glycolytic genes exhibited upregulation. (I) Heatmap showed the differences of metabolites abundance between two groups with indicated treatment. (J-K) Integrated analysis identified FOXO3 as a potentially downregulated TF with a potential interaction with miR-1293 in PDACs. (L-M) The results of a luciferase reporter assay provided supporting evidence for the binding of miR-1293 to FOXO3 mRNA (mean ± SD). (N) Western blot analysis demonstrated that miR-1293 reduces the expression of FOXO3.

Article Snippet: The membranes were subsequently probed with primary antibodies targeting the following proteins: FOXO3A (Proteintech, 66428–1-Ig), TSG101 (Abcam, ab125011), Calnexin (SAB, 12186), CD86 (41779), CD9 (Boster, BM4212) and β-actin (66009–1-lg, Proteintech).

Techniques: Transfection, Expressing, Cell Culture, Luciferase, Reporter Assay, Binding Assay, Western Blot